Home Stock list Creative Medical Technology: Cancellation/Violation of Listing Rule/Transfer of Listing – Form 8-K

Creative Medical Technology: Cancellation/Violation of Listing Rule/Transfer of Listing – Form 8-K

0
celz_8k.htm

UNITED STATES

SAFETY AND EXCHANGES COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Report date (date of first reported event): July 8, 2022

Creative Medical Technology Holdings, Inc.

(Exact name of the declarant as specified in its charter)

Nevada

000-53500

87-0622284

(State or other jurisdiction

of incorporation)

(Commission

File number)

(IRS Employer

ID number)

211 E Osborn Road, Phoenix, AZ85012

(Address of main executive offices)

(480) 399-2822

(Telephone number of holder, including area code)

Check the appropriate box below if the filing of Form 8-K is intended to concurrently satisfy the filer’s filing obligation under any of the following provisions:

Written communications pursuant to Rule 425 of the Securities Act (17 CFR 230.425)

Solicit material in accordance with Rule 14a-12 of the Exchange Act (17 CFR 240.14a-12)

Pre-opening communications pursuant to Rule 14d-2(b) of the Exchange Act (17 CFR 240.14d-2(b))

Pre-opening communications pursuant to Rule 13e-4(c) of the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trade

Symbol(s)

Name of each exchange listed on

Common shares, par value $0.001 per share

CELZ

The Nasdaq Stock Market LLC

Indicate with a check mark whether the registrant is an emerging growth company within the meaning of Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b -2) .

Emerging growing business ☐

If the company is an emerging growth company, indicate with a check mark whether the registrant has elected not to use the extended transition period to comply with new or revised financial accounting standards under the section 13(a) of the Exchange Act. ☐

Item 3.01. Notice of deregistration or non-compliance with a rule or standard for maintaining registration; Registration transfer.

On July 8, 2022, Creative Medical Technology Holdings, Inc. (the “Company”) received a letter from the Nasdaq Stock Market stating that the Company was not in compliance with Nasdaq listing rule 5550(a)(2). ) because the closing offer price of the Company’s common stock was less than $1.00 per share for 30 consecutive business days. The opinion has no immediate impact on the Company’s listing.

Under Nasdaq listing rules, the company has a 180-day grace period, until January 4, 2023, during which the company can revert to compliance if the bid price for its common stock closes at 1, $00 per share or more for a minimum of ten consecutive trades. days. The Company may be eligible for an additional 180-day grace period if the Company meets the Nasdaq Initial Listing Standards (other than with respect to minimum offering price) for the Nasdaq Capital Market.

The Company intends to actively monitor the bid price for its common stock through January 4, 2023 and will review available options to restore compliance with the Nasdaq minimum bid price requirements.

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

Creative Medical Technology Holdings, Inc.

Date: July 14, 2022

By:

/s/ Timothy Warbington

Timothy Warbington, Managing Director